What happened with ATRC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
AtriCure supplies devices that surgeons use in open-heart and minimally invasive procedures. Its ablation instruments use radiofrequency energy or freezing to treat heart tissue for atrial fibrillation, while its implantable AtriClip devices close off the left atrial appendage. These two treatment areas account for most of its revenue. It also sells Cryo Nerve Block products, including cryoSPHERE, which temporarily freeze peripheral nerves during surgery to relieve postoperative pain as the nerves regenerate.
Medical centers pay for the devices and disposable instruments used in procedures. AtriCure generally places generators with direct customers and sells the disposable handpieces and probes that connect to them; AtriClip is supplied with a disposable applicator. Most revenue comes from the United States. The company sells directly there and in selected overseas markets, and sells through distributors elsewhere.
Sales depend on physicians adopting these treatments and payers covering the procedures. Clinical evidence, physician training and reimbursement therefore matter to demand. AtriCure can promote products for atrial fibrillation treatment, stroke prevention or reduction of postoperative atrial fibrillation only for uses that have regulatory clearance or approval. Isolator Synergy and EPi-Sense have FDA approval for certain atrial fibrillation treatments in specified procedures, not unrestricted approval across those uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Medtronic is AtriCure’s primary rival for medical centers buying surgical heart-ablation and left atrial appendage-management devices. Watch Medtronic’s product launches in those two areas for changes in the alternatives available to AtriCure’s customers.
Boston Scientific offers alternatives to the surgical devices AtriCure sells to medical centers: its FARAPULSE treats atrial fibrillation through catheter ablation, while WATCHMAN closes the left atrial appendage through a catheter rather than surgery.
Abbott competes with the surgical treatments AtriCure sells to medical centers through its electrophysiology ablation devices for atrial fibrillation and its Amulet device for closing the left atrial appendage.
Johnson & Johnson’s Biosense Webster sells catheter ablation systems that can replace or work alongside AtriCure’s surgical atrial fibrillation devices used by medical centers. Watch the shift toward catheter treatment: AtriCure said physicians’ adoption of pulsed-field ablation catheters reduced Hybrid procedures, pushing its minimally invasive ablation revenue down 31.2% in 2025.
Pulse Biosciences, Inc is developing cardiac ablation technology to compete with the established surgical ablation devices AtriCure sells to medical centers. It remains an emerging challenger: its 2025 product revenue came from limited-market sales of the Vybrance Percutaneous Electrode System, not reported sales of cardiac ablation devices.
Artivion shares AtriCure’s exposure to cardiac surgery: it supplies heart valves, aortic devices and preserved cardiac tissues for operations that can also use AtriCure’s ablation and appendage-management devices. Its On-X valve sales and cardiac-tissue preservation revenue offer another window on the surgical activity behind AtriCure’s open-heart business.
AtriCure, Inc. earningsThis company
AtriCure’s report will show whether sales growth in open ablation, appendage management and pain management can offset the decline in minimally invasive ablation and improve operating results.
Read revenue across the businesses alongside gross margin and operating loss. Continued growth in open ablation, appendage management and pain management, a smaller decline in minimally invasive ablation, stable margins and a narrower loss would show that growth is broadening and improving the economics. If growth is concentrated in fewer businesses while minimally invasive ablation keeps falling, margins weaken or the loss widens, sales growth is not yet producing better overall operating results.
Artivion, Inc. earningsAORT
Artivion’s report will show whether valve sales and cardiac-tissue preservation offer signs of stronger or weaker activity in the open-heart surgeries that can also use AtriCure’s devices.
Read On-X valve sales alongside cardiac-tissue preservation revenue. Growth in both would point to firmer activity in a surgical setting that also uses AtriCure’s open-heart products; declines in both would suggest that setting may be softer. The companies serve different products and procedure mixes, so this is context on the surgical backdrop, not proof that AtriCure’s sales moved the same way.
Medtronic plc earningsMDT
Medtronic’s report will show how medical centers are adopting its surgical heart-ablation and left atrial appendage-management products, where it competes directly with AtriCure.
Look for what Medtronic says about progress and adoption in these two product areas, and whether it has added new options for medical centers. Stronger uptake or new products that widen those options would point to more competitive pressure on AtriCure in the same treatment areas; limited progress would offer less evidence of rising pressure, but would not by itself show how AtriCure’s sales are changing.
